Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.22485 | DOI Listing |
Publication Analysis
Top Keywords
whole-brain atrophy
16
measure progression
8
huntington's disease
8
atrophy rates
8
whole-brain
4
atrophy measure
4
progression premanifest
4
premanifest early
4
early huntington's
4
disease therapeutic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!